Recent developments

at Tullis and our portfolio companies

News

Keeping you current on new and follow-on investments, portfolio product and service milestones, publications and events, management and board transitions, and other developments in Tullis funds.

January

9

ATEC Announces Select Preliminary Financial 2022 Results, 2023 Guidance and Closing of Flexible, Non-Dilutive Debt Facility

CARLSBAD, Calif.–(BUSINESS WIRE)– Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to...

20

electroCore, Inc. Launches New Wellness Product Offering for Stress, Anxiety and Sleep

Truvaga™ handheld non-invasive vagus nerve stimulator offers drug-free 2-minute sessions ROCKAWAY, N.J., Dec. 20, 2022 (GLOBE...

15

TriSalus Life Sciences Highlights Pressure-Enabled Regional Immuno-Oncology™ (PERIO™) Clinical Trial Progress and Pre-clinical Research Developments

Studies evaluating methods to overcome two major challenges in treating patients with liver and...

7

electroCore Announces Issuance of Two New U.S. Patents

Expansion of patent portfolio allows exploration of the role of nVNS beyond migraine and...

20

TriSalus Life Sciences Provides Updates on Pressure-Enabled Regional Immuno-Oncology™ (PERIO™) 01 and 02 Clinical Studies

Data further substantiates potential to significantly improve immunotherapy outcomes for patients with liver and...

18

gammaCore Sapphire™ Non-Invasive Vagus Nerve Stimulator (nVNS) Receives Unique National Product Code Number by the Belgian Pharmaceutical Association

ROCKAWAY, N.J., Nov. 18, 2022 (GLOBE NEWSWIRE) — electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage...

14

Exagen Inc. Reports Third Quarter 2022 Results

Medicare Reimbursement Returns SAN DIEGO, Nov. 14, 2022 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of...

14

TriSalus Life Sciences to Become Publicly Traded Through Merger with MedTech Acquisition Corporation

Oncology Therapeutics Company Focused on Transforming Cancer Treatment with Proprietary Innovative Therapies and Disruptive...

3

ATEC Reports Third Quarter 2022 Financial Results

Total revenue grew 43% to $90 million, including surgical revenue growth of 53% EOS...

3

electroCore Announces Third Quarter 2022 Financial Results

Third quarter 2022 revenue grew 33% over third quarter 2021 ROCKAWAY, N.J. , Nov. 03, 2022 (GLOBE NEWSWIRE) —...

1

electroCore, Inc. Announces Distribution Agreement with Joerns Healthcare, LLC

ROCKAWAY, N.J., Nov. 01, 2022 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company,...

20

gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Improves Neurobehavioral Outcomes in a Model of Traumatic Brain Injury

Pre-clinical trial demonstrates ability of nVNS to decrease amount of brain injury, decrease anxiety...

Recent developments

News

January

9

ATEC Announces Select Preliminary Financial 2022 Results, 2023 Guidance and Closing of Flexible, Non-Dilutive Debt Facility

December

20

electroCore, Inc. Launches New Wellness Product Offering for Stress, Anxiety and Sleep

December

15

TriSalus Life Sciences Highlights Pressure-Enabled Regional Immuno-Oncology™ (PERIO™) Clinical Trial Progress and Pre-clinical Research Developments

December

7

electroCore Announces Issuance of Two New U.S. Patents

November

20

TriSalus Life Sciences Provides Updates on Pressure-Enabled Regional Immuno-Oncology™ (PERIO™) 01 and 02 Clinical Studies

November

18

gammaCore Sapphire™ Non-Invasive Vagus Nerve Stimulator (nVNS) Receives Unique National Product Code Number by the Belgian Pharmaceutical Association

November

14

Exagen Inc. Reports Third Quarter 2022 Results

November

14

TriSalus Life Sciences to Become Publicly Traded Through Merger with MedTech Acquisition Corporation

November

3

ATEC Reports Third Quarter 2022 Financial Results

November

3

electroCore Announces Third Quarter 2022 Financial Results

November

1

electroCore, Inc. Announces Distribution Agreement with Joerns Healthcare, LLC

October

20

gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Improves Neurobehavioral Outcomes in a Model of Traumatic Brain Injury